معرفی
Professor Amanda Adler holds dual roles as Professor of Diabetic Medicine and Health Policy at the University of Oxford and Director of the Diabetes Trials Unit (DTU). She concurrently serves as Honorary Consultant Physician, Commissioner on the Commission on Human Medicines (CHM), and Vice-Chair of NICE's Technology Appraisal Committee. Her work bridges clinical research, policy evaluation, and global health initiatives.
Education: Trained in economics, medicine, and epidemiology in the US, followed by specialized studies in pharmacovigilance and pharmacoepidemiology in the UK. Professional roles include 12 years as Chair of NICE's Technology Appraisal Committee and leadership in global health organizations like the WHO Technical Advisory Group for Diabetes.
Research focuses on diabetes interventions, health policy development, and clinical trial methodologies. The DTU collaborates internationally on studies funded by industry, NIHR, and charities. Recent publications emphasize biomarker discovery, frailty in diabetes trials, and medication safety.
Awards: Recognized with the Distinguished Contribution to NICE Award (2024) for her 20-year impact on NICE guidelines. Professional affiliations include Fellowships at the Royal College of Physicians and Royal Statistical Society.
Advising/grants: Supervises graduate students and chairs multiple national/international committees including CHM's Cardiovascular, Diabetes, Renal, Respiratory and Allergy Expert Advisory Group. Leads projects on universal health coverage priorities for institutions like the World Bank and OECD.
